MX9304878A - Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis. - Google Patents

Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.

Info

Publication number
MX9304878A
MX9304878A MX9304878A MX9304878A MX9304878A MX 9304878 A MX9304878 A MX 9304878A MX 9304878 A MX9304878 A MX 9304878A MX 9304878 A MX9304878 A MX 9304878A MX 9304878 A MX9304878 A MX 9304878A
Authority
MX
Mexico
Prior art keywords
azaspiran
substituted
psoriasis
manufacture
treatment
Prior art date
Application number
MX9304878A
Other languages
English (en)
Inventor
Alison Mary Badger
Don Edgar Griswold
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX9304878A publication Critical patent/MX9304878A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Se describe un método para tratar psoriasis en un mamífero que requiere del mismo, que comprende administrar a dicho mamífero una cantidad efectiva de un azaspirano substituido.
MX9304878A 1992-08-13 1993-08-11 Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis. MX9304878A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929217116A GB9217116D0 (en) 1992-08-13 1992-08-13 Methods

Publications (1)

Publication Number Publication Date
MX9304878A true MX9304878A (es) 1994-05-31

Family

ID=10720232

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304878A MX9304878A (es) 1992-08-13 1993-08-11 Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.

Country Status (12)

Country Link
US (1) US5981538A (es)
EP (1) EP0654996A4 (es)
JP (1) JPH08500120A (es)
KR (1) KR950702830A (es)
CN (1) CN1037815C (es)
AU (1) AU670970B2 (es)
CA (1) CA2142223A1 (es)
GB (1) GB9217116D0 (es)
MX (1) MX9304878A (es)
NZ (1) NZ255753A (es)
WO (1) WO1994004150A1 (es)
ZA (1) ZA935831B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9217121D0 (en) * 1992-08-13 1992-09-23 Smithkline Beecham Corp Methods
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
BG62359B1 (bg) * 1995-07-13 1999-09-30 Anormed N,n-диетил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанаминдималеат
US5843936A (en) * 1996-06-28 1998-12-01 Bernstein; Lawrence R. Topical administration of azaspiranes to prevent or treat skin conditions associated with hyperproliferation of keratinocytes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
AU658577B2 (en) * 1990-08-10 1995-04-27 Smithkline Beecham Corporation Immunosuppressive compositions
WO1992004899A1 (en) * 1990-09-24 1992-04-02 Smithkline Beecham Corporation Methods

Also Published As

Publication number Publication date
EP0654996A4 (en) 1997-09-17
ZA935831B (en) 1995-01-18
JPH08500120A (ja) 1996-01-09
KR950702830A (ko) 1995-08-23
AU5010193A (en) 1994-03-15
EP0654996A1 (en) 1995-05-31
CN1100932A (zh) 1995-04-05
GB9217116D0 (en) 1992-09-23
CN1037815C (zh) 1998-03-25
NZ255753A (en) 1999-06-29
WO1994004150A1 (en) 1994-03-03
CA2142223A1 (en) 1994-03-03
US5981538A (en) 1999-11-09
AU670970B2 (en) 1996-08-08

Similar Documents

Publication Publication Date Title
MX9703354A (es) Composiciones para tratar el acné y curar heridas que contienen un piruvato, un antioxidante y una mezcla de acidos grasos.
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ES2059965T3 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
NO174764C (no) Fremgangsmåte for fremstilling av et preparat som er virksomt ved behandling av hyperkeratotiske og andre hudsykdommer
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
ES2080837T3 (es) Tratamiento de estados y enfermedades.
ES2157958T3 (es) Uso de venlafaxina o de un compuesto de ariloxipropanamina para la preparacion de un medicamento para el tratamiento de la incontinencia urinaria.
AR009507A1 (es) Utilizacion de retinoides
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
ES2011120A6 (es) Forma de dosificacion para tratar las enfermedades cardiovasculares.
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
DK71387A (da) Terapeutisk middel til behandling af psoriasis
ES2121779T3 (es) Utilizacion de espiperona como agente inmunosupresor y antiinflamatorio.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
MX9304185A (es) Producto y composicion farmaceutica que lo contiene para el tratamiento de la mastitis y la mestritis bovina.
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
ES2134184T3 (es) Empleo de etisterona para el tratamiento topico del acne o de la alopecia androgenetica.
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
MX9206135A (es) Metodos

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees